Abstract:OBJECTIVE:To evaluate the long-term efficacy of infant hepatitis B (HB) immunization program on preventing hepatitis B virus (HBV) infection, and to assess its impact on the incidence of HB in children.METHODS:Since 1986, the universal HB vaccination for newborn babies with standard, pediatric dose had been launched without serologic prescreening of pregnant women for HBsAg, in a high endemic county of Long-An. A hepatitis surveillance system was set up to evaluate the possible impact on the incidence of hepatitis B. To serologically evaluate the effectiveness of the program, a stratified random sampling of 1000 children in 1987 birth cohorts, who received plasma-derived HB vaccine, was recruited for long-term follow up at the age of 1 to 13 years. A cross-sectional seroepidemiological survey was conducted in the county in 1985, before the program, and in 2001, for 1551 children born in 1996-2000 who were administered yeast recombinant HB vaccine.RESULTS:During the 1 to 13 years after the program, the rates of HBsAg-positive were 0.7% to 2.9% with an average of 1.7% and the protective rates were 83.5% to 96.6%. HBV infection rates were 1.1% tp 5.1% with an average of 2.4% and the protective rates were 93.5% to 98.4%. For the population aged 1 to 4 years who were immunized with recombinant HB vaccine, HBsAg positive rates were 1.8% to 2.4% with an average of 2.0% and the protective rates were 78.4 to 85.2%. 14 years after the program, the cumulative incidence of acute hepatitis B in the children aged 1 to 14 years fell to 1.5 cases per 100,000 children, down 91.8% as compared with that in 1985 to 1987. However, the cumulative incidence of 14.4 cases per 100,000 population in unvaccinated children was not significantly different from that in the history controls. Acute hepatitis B children had not been reported, showing that the vaccination program was 100% protective in children.CONCLUSION:The universal infant HB vaccination program in a hyperendemic area has proved to be effective in controlling HBV infection and decreasing the incidence of acute hepatitis B in children. Booster dose is unnecessary in 13 years after the immunization. The protective efficacy of yeast recombinant HB vaccine is similar to that of plasma-derived HB vaccine.

[Long-Term Efficacy Study of Hepatitis B Vaccination in Newborns--results of 11 Years' Follow-Up].

Monitoring the Efficacy of Infant Hepatitis B Vaccination and Revaccination in 0- to 8-Year-old Children: Protective Anti-Hbs Levels and Cellular Immune Responses.

[Long-Term Efficacy of Vaccination Against Hepatitis B in Newborns: 13 Years' Follow-Up].

An observation on the long-term efficacy of recombinant hepatitis B vaccines among the newborns

Long-term Evaluation of Immune Efficacy among Newborns 16 Years after HBV Vaccination

The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: a 5-year follow-up study.

Long-term Efficacy of Infant Hepatitis B Immunization Program

Long-term Protection of Infants Against Hepatitis B by Neonatal Immunoprophylaxis Born from Mothers Infected with Hepatitis B Virus

Strategies for Hepatitis B Booster Vaccination among Children: an 8-Year Prospective Cohort Study

The One Year Effects of Three Doses of Hepatitis B Vaccine As a Booster in Anti-Hbs-negative Children 11–15 Years after Primary Immunization; China, 2009–2011

Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization.

Long-term efficacy of recombinant hepatitis B vaccine and risk of natural infection in infants born to mothers with hepatitis B e antigen

Long-term Effect of Plasma-derived Vaccine in the Prevention of Hepatitis B (eighteen Years'Follow-up Study)

The long-term efficacy of recombinant hepatitis B vaccines for children

Comparative Long Term Immunogenicity of Two Recombinant Hepatitis B Vaccines and the Effect of a Booster Dose Given After Five Years in a Low Endemicity Country

[Valuation on the Immunization Efficacy on the 23 Years Who Had Received Plasma-Derived HBV Vaccine As Newborns].

Study on Effect and Duration of Hepatitis B Vaccine Made by Deoxyribonucleic Acid Techniques with Saccharomyces Cerevisiae Yeast after Long-term Vaccination

The Immune Effect of Blood-borne Hepatitis B Vaccine 20 Years after Vaccination

The antibody persistence after immunisation with hepatitis B vaccine combined with different doses of hepatitis B immunoglobulin among infants born by HBsAg positive mothers: a three-year following-up study

The 13-year-lasting efficacy of yeast-derived hepatitis B vaccines among the newborns

Long-Term Efficacy And Immune Memory Of Neonatal Recombinant Hepatitis B Vaccination In Adolescents Aged 13-14 Years